SAN DIEGO, July 27, 2011 /PRNewswire/ — Visionary
Pharmaceuticals, Inc., announced today that the company has raised
seed round investments from a consortium of Angel Investors. The
company is using the capital to develop novel small molecule
retinoic acid related orphan receptor (ROR) modulators targeting
TH17 T-lymphocytes for the treatment of various autoimmune
disorders including rheumatoid arthritis, multiple sclerosis,
psoriasis and COPD.
Visionary Pharmaceuticals has created BindingSIGHTs, a
proprietary computational technology platform which encompasses an
advanced suite of structural biology and chemical informatic tools.
BindingSIGHTs enables sophisticated virtual screening and
structure-based drug design for challenging molecular drug targets.
Visionary Pharmaceuticals has also created the MANIFOLD virtual
compound library of more than 22 million compounds, which have been
screened against ROR BindingSIGHTs fingerprints. High-scoring
drug-like hits have been docked to structural models of the ROR
ligand binding site to yield focused compound sets. These compounds
are synthesized and screened in cell-based assays providing novel
highly ligand-efficient chemical matter to drive structure-based
drug discovery.
Visionary Pharmaceuticals has created an innovative drug
discovery engine utilizing novel proprietary technology to focus on
nuclear hormone receptors. Nuclear hormone receptor modulators
represent 15% of all drugs approved in the US and account for more
than $27 billion in annual sales. “Our BindingSIGHTs technology and
MANIFOLD library enables us to save both time and money in
generating the best possible lead series. With the initial seed
round investments we are now able to launch full-scale research
activities in our state-of-the-art labs,” said Gordon Alton, Ph.D.,
President and CEO of Visionary Pharmaceuticals. “We have assembled
a veteran leadership team with proven expertise in driving novel
therapies to IND. Additionally, o
‘/>”/>
